Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 0.00 0.00%
S&P 500 1,878.61 3.22 0.17%
NASDAQ 4,148.34 21.37 0.52%
Ticker Volume Price Price Delta
STOXX 50 3,166.66 -23.15 -0.73%
FTSE 100 6,688.04 -14.96 -0.22%
DAX 9,461.41 -87.27 -0.91%
Ticker Volume Price Price Delta
NIKKEI 14,429.26 24.27 0.17%
TOPIX 1,169.99 5.09 0.44%
HANG SENG 22,223.53 -339.27 -1.50%

AHF: J&J’s Record $2 Billion Fine Shows Pharma’s ‘Unbridled Greed’



  AHF: J&J’s Record $2 Billion Fine Shows Pharma’s ‘Unbridled Greed’

 Department of Justice fines Johnson & Johnson a record $2.2 billion; Action
 underscores a growing pattern of abuse fueled by the unbridled greed of J&J
                  and others in the pharmaceutical industry

Last week, AHF sued Johnson & Johnson in the Superior Court of California for
 cheating on its AIDS drug pricing, overcharging AHF by as much as $2 million
                     on HIV/AIDS drugs between 2005-2012

Business Wire

LOS ANGELES -- November 5, 2013

As news broke yesterday that the United States Department of Justice leveled a
$2.2 billion fine against Johnson & Johnson (J&J) to settle civil and criminal
charges that the pharmaceutical giant illegally marketed one of its
antipsychotic drugs and other medications for off-label use as well as paid
illegal kickbacks to a pharmacy, the AIDS Healthcare Foundation (AHF), the
largest global AIDS organization, noted that the DOJ’s action and record fine
against J&J underscores the unbridled greed of the entire pharmaceutical
industry.

“Kudos to the Justice Department for holding J&J, one of America’s most
trusted brands—from Johnson’s baby powder and shampoo to Tylenol and its
prescription medications—accountable for its illegal, and quite brazen,
marketing activities and kickbacks,” said Michael Weinstein, President of AHF.
“Sadly, this DOJ action underscores a growing pattern of abuse by Pharma and
epitomizes the unbridled greed of both J&J and the pharmaceutical industry as
a whole.”

Separately, AHF last week sued Johnson & Johnson and its subsidiaries in the
Superior Court of California for cheating on its AIDS drug pricing and
overcharged AHF by as much as $2 million on HIV/AIDS drugs purchased between
2005-2012. AHF’s lawsuit alleges that the companies have “…failed to fully
satisfy their obligations with respect to the drugs they sold to AHF over a
period of many years,” under the 340B Program, a Federal drug discount program
designed to stretch scarce Federal resources as far as possible for safety net
healthcare providers such as AHF. The J&J Companies include Johnson & Johnson,
Janssen Therapeutics and Janssen Biotech. Together, they control a significant
portion of the AIDS drug market with drugs that include Prezista, Intelence,
Endurant and Procrit.

AHF’s lawsuit against J&J was filed Wednesday, October 30, 2013 in the
Superior Court of California, County of Los Angeles, Central District [case
#BC526253]. The action against J&J includes claims of “Violation of California
Unfair Competition Law; Breach of Contract—Third Party Beneficiary;
Negligence; Unjust Enrichment and Breach of Covenant of Good Faith and Fair
Dealing.”

About AIDS Healthcare Foundation

AIDS Healthcare Foundation (AHF), the largest global AIDS organization,
currently provides medical care and/or services to more than 250,000
individuals in 32 countries worldwide in the US, Africa, Latin
America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more
about AHF, please visit our website: www.aidshealth.org, find us on Facebook:
www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare.

Contact:

AIDS Healthcare Foundation
Ged Kenslea, Senior Director, Communications
Tel: (323) 308-1833, Cell: (323) 791-5526
gedk@aidshealth.org
or
AIDS Healthcare Foundation
Laura Boudreau, Chief Counsel for Operations
Tel: (323) 860-5202
laura.boudreau@aidshealth.org
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement